Lonza nominates Pearl Huang. Lonza Group stock gains 1.84 percent.

Published on 10/06/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Half-Year 2026 sales rose 16.00 percent to CHF 3.4 billion. Lonza Group stock costs EUR 629.70 versus EUR 618.30, plus 1.84 percent.

Isometrische 3D-Illustration einer Pharma-Produktionsanlage mit Tanks, Leitungen und Verpackungslinie — Lonza CH0013841017 isometrische 3D Pharma Anlage mit Tanks Leitungen und Verpackungs Linie, Illustration mit AI erstellt.

Lonza nominated Pearl Huang as an independent board member on September 30, 2026, while Lonza Group stock was trading at EUR 629.70 at Lang & Schwarz on October 6, 2026, up 1.84 percent versus the prior close of EUR 618.30. The nomination is subject to approval at the annual meeting in May 2027, according to FT.

Board renewal supports CDMO strategy

Pearl Huang brings pharmaceutical and biotechnology leadership experience, including prior roles at Roche, GSK and Merck. The same release says two long-serving directors will not stand for re-election at the 2027 annual meeting, leaving Lonza with eight new board members since 2024.

The board changes arrive as Lonza continues its shift toward a pure-play contract development and manufacturing organization. At the September 15, 2026 Morgan Stanley conference, management said the company expects to complete the divestment of 60.00 percent of Capsules and Health Ingredients by year-end 2026, as reported by Investing.com.

Half-Year 2026 growth meets normalization risk

Lonza generated CHF 3.4 billion in sales and CHF 1.2 billion in Core EBITDA in Half-Year 2026, according to the company announcement carried by FT. A transcript of the September 15 conference reports that Advanced Synthesis grew 28.00 percent in the first half of 2026, but its 48.00 percent EBITDA margin is viewed as a peak rather than a sustainable level.

That comparison matters because management described a more normal Advanced Synthesis margin near 40.00 percent. Integrated Biologics is expected to grow 10.00 percent in 2026, with capacity timing rather than demand weakness limiting expansion, while capital spending is expected to normalize to 14.00 percent to 19.00 percent of sales.

Stock gains while investors assess execution

The current session gives the market a positive reference point, with the Lang & Schwarz quote 1.84 percent above its prior close. The operational picture is more balanced: strong first-half growth and a focused CDMO strategy are set against margin normalization and continued investment in new capacity.

Lonza was trading at EUR 629.70 at Lang & Schwarz on October 6, 2026 at 1:41 p.m. CEST, compared with a prior close of EUR 618.30. The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.